Trial Profile
A prospective, open-labelled, randomized, multicenter phase II study to evaluate efficacy and safety of Erlotinib vs NP chemotherapy as adjuvant therapy in post radical operation NSCLC patients with EGFR19 or 21 exon mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EVAN
- 26 Aug 2022 Results at the 43 month follow-up published in the Journal of Clinical Oncology
- 08 Jun 2021 Status changed from active, no longer recruiting to completed as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 5-year OS and exploratory results from EVAN with a further 43 month follow up presented at the 57th Annual Meeting of the American Society of Clinical Oncology